Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N02CD05
|
| gptkbp:brand |
gptkb:Ajovy
|
| gptkbp:CASNumber |
1446214-23-9
|
| gptkbp:developedBy |
gptkb:Teva_Pharmaceutical_Industries
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
IgG2Δa monoclonal antibody
|
| gptkbp:mechanismOfAction |
CGRP antagonist
|
| gptkbp:pregnancyCategory |
not assigned (US)
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
injection site reactions
hypersensitivity reactions |
| gptkbp:target |
gptkb:calcitonin_gene-related_peptide_(CGRP)
|
| gptkbp:UNII |
6B9Y2V4F3E
|
| gptkbp:usedFor |
migraine prevention
|
| gptkbp:bfsParent |
gptkb:Ajovy
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
fremanezumab
|